TiumBio to Begin Phase 2 Study for TU2218 in Cancer Therapy
Tuesday, March 12, 2024
TiumBio Co., Ltd. (KOSDAQ: 321550), a clinical-stage biopharmaceutical firm specializing in discovering and developing innovative treatments for rare and incurable diseases, recently disclosed significant progress in its drug development efforts.
In late February 2024, TiumBio filed an Investigational New Drug (IND) application with the Korean Ministry of Food and Drug Safety (MFDS) for TU2218, an oral immuno-oncology drug. This submission represents a pivotal moment in their quest to address unmet medical needs in cancer care.
TU2218, a pioneering oral dual inhibitor targeting transforming growth factor beta receptor 1 (TGFR1) and vascular endothelial growth factor receptor 2 (VEGFR2), aims to boost the efficacy of immuno-oncology drugs by blocking these pathways. Presently, TiumBio is conducting a Phase 1b clinical trial of TU2218 in combination with Keytruda (pembrolizumab) for advanced solid tumors in the U.S.
The Phase 2a study, focusing on biliary tract cancer (BTC), head and neck squamous cell carcinoma (HNSCC), and colorectal cancer (CRC), seeks to enroll up to 116 participants across three cohorts. This trial will evaluate the safety and efficacy of TU2218 when administered alongside pembrolizumab.
TiumBio's preclinical findings, set to be presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting, highlight TU2218's potential in combination therapies. Notably, the triple combination regimen involving TU2218 demonstrated significant tumor growth inhibition and complete response rates compared to control groups in various tumor models.
Dr. Hun-taek Kim, Founder and CEO of TiumBio, expressed confidence in TU2218's ability to address the challenges encountered in cancer treatment. He emphasized the company's dedication to developing safer and more effective therapies to improve clinical outcomes for patients.
Source: tiumbio.com
